The association of C-reactive protein with subclinical cardiovascular disease in HIV-infected and HIV-uninfected women

Caitlin Moran, Emory University
Anandi Sheth, Emory University
Christina Mehta, Emory University
David B. Hanna, Albert Einstein College of Medicine
Deborah R. Gustafson, State University of New York-Downstate
Michael W. Plankey, Georgetown University
Wendy J. Mack, University of Southern California
Phyllis C. Tien, University of California, San Francisco
Audrey L. French, Stroger Hospital of Cook County
Elizabeth T. Golub, Johns Hopkins University

Only first 10 authors above; see publication for full author list.

Journal Title: AIDS
Volume: Volume 32, Number 8
Publisher: Lippincott, Williams & Wilkins | 2018-05-15, Pages 999-1006
Type of Work: Article | Post-print: After Peer Review
Permanent URL: https://pid.emory.edu/ark:/25593/tqknn

Final published version: https://insights.ovid.com/pubmed?pmid=29438198

Copyright information:
© 2018 Wolters Kluwer Health, Inc. All rights reserved.

Accessed December 1, 2019 1:53 PM EST
The Association of C-Reactive Protein with Subclinical Cardiovascular Disease in HIV-infected and HIV-uninfected Women

Caitlin A. MORAN1,2, Anandi N. SHETH1,2, C. Christina MEHTA3, David B. HANNA4, Deborah R. GUSTAFSON5, Michael W. PLANKEY6, Wendy J. MACK7, Phyllis C. TIEN8, Audrey L. FRENCH9, Elizabeth T. GOLUB10, Arshed QUYYUM1, Robert C. KAPLAN4, and Ighovwerha OFOTOKUN1,2

1Department of Medicine, Emory University, Atlanta, GA 30322, USA
2Grady Healthcare System, Atlanta, GA 30303, USA
3Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA 30322, USA
4Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA
5Department of Neurology, State University of New York- Downstate, Brooklyn, NY 11203, USA
6Department of Medicine, Georgetown University Medical Center, Washington, DC 20007, USA
7Department of Preventive Medicine, University of Southern California, Los Angeles, CA 90033, USA
8Department of Medicine, University of Southern California- San Francisco and the Department of Veterans Affairs, San Francisco, CA 94121, USA
9Department of Medicine, Stroger Hospital of Cook County and Rush University Medical Center, Chicago, IL 60612, USA
10Department of Epidemiology, Johns Hopkins University, Baltimore, MD 21205, USA

Abstract

Objective—HIV is a cardiovascular disease (CVD) risk factor. However, CVD risk is often underestimated in HIV-infected women. C-reactive protein (CRP) may improve CVD prediction in this population. We examined the association of baseline plasma CRP with subclinical CVD in women with and without HIV.

Design—Retrospective cohort study
Methods—572 HIV-infected and 211 HIV-uninfected women enrolled in the Women’s Interagency HIV Study underwent serial high-resolution B-mode carotid artery ultrasonography between 2004-2013 to assess carotid intima-media thickness (CIMT) and focal carotid artery plaques. We used multivariable linear and logistic regression models to assess the association of baseline high (≥3 mg/l) high-sensitivity (hs) CRP with baseline CIMT and focal plaques, and used multivariable linear and Poisson regression models for the associations of high hsCRP with CIMT change and focal plaque progression. We stratified our analyses by HIV status.

Results—Median (IQR) hsCRP was 2.2 mg/l(0.8-5.3) in HIV-infected, and 3.2 mg/l(0.9-7.7) in HIV-uninfected, women (p=0.005). There was no statistically significant association of hsCRP with baseline CIMT [adjusted mean difference -3.5 μm (95%CI:-19.0-12.1)] or focal plaques [aOR:1.31(0.67-2.67)], and no statistically significant association of hsCRP with CIMT change [adjusted mean difference 11.4 μm(-2.3-25.1)]. However, hsCRP ≥3 mg/l was positively associated with focal plaque progression in HIV-uninfected [aRR:5.97(1.46-24.43)], but not in HIV-infected [aRR:0.81(0.47-1.42)] women (p=0.042 for interaction).

Conclusion—in our cohort of women with similar CVD risk factors, higher baseline hsCRP is positively associated with carotid plaque progression in HIV-uninfected, but not HIV-infected, women, suggesting that subclinical CVD pathogenesis may be different HIV-infected women.

Keywords
HIV; subclinical CVD; C-reactive protein; atherosclerosis; women

Introduction
Persons living with human immunodeficiency virus (HIV) who are treated with antiretroviral therapy (ART) can expect to attain a near-normal life expectancy [1]; however, they have an increased risk of age-related comorbidities, including cardiovascular disease (CVD) [2]. Compared with the general population, HIV-infected individuals have greater rates of myocardial infarctions (MIs) and ischemic strokes, especially at younger ages [3-7]. Additionally, although the incidence of CVD is greater among men than women, the relative contribution of HIV to CVD risk may be greater among HIV-infected women than HIV-infected men: in observational studies, HIV-infected women had a 2-3-fold increased risk of MI and stroke compared with their HIV-uninfected counterparts, while HIV-infected men had an approximately 1.5-fold increased risk [6-9]. However, CVD risk prediction tools, including the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Pooled Cohort equations, do not include HIV as a CVD risk factor, and underestimate CVD risk in HIV-infected individuals [10, 11], particularly among women and minority populations [12].

There is a clear need to improve CVD risk assessment in these populations. C-reactive protein (CRP) is an acute phase reactant associated with subclinical CVD progression and clinical CVD in the general population [13, 14], and is included in the ACC/AHA guidelines as an option to improve risk-stratification among intermediate-risk persons [10]. However, its association with both subclinical and hard clinical CVD outcomes in the HIV population is less clear [15, 16], and data in HIV-infected women are particularly lacking. To determine
the association of CRP with subclinical CVD prevalence and progression among HIV-infected women, we retrospectively analyzed data from the Women’s Interagency HIV Study (WIHS) carotid ultrasound substudy, in which measures of subclinical CVD, including carotid intima-media thickness (CIMT) and carotid plaque formation, which are associated with subsequent clinical CVD events [17], were obtained. We tested for differences in association by HIV serostatus.

Materials and Methods

Study population

WIHS is a multi-site, longitudinal cohort of HIV-infected and at-risk HIV-uninfected women in the United States [18]. Study design has been described previously [18, 19]. Briefly, participants undergo semiannual detailed interviews, physical examinations, and specimen collections. In 2004, WIHS initiated a longitudinal carotid artery ultrasound substudy; all WIHS participants at all six clinical sites were eligible for enrollment in the substudy [20]. For this retrospective analysis, we included all substudy participants with at least two carotid artery ultrasound substudy visits who had high sensitivity (hs) CRP measured at the baseline substudy visit. WIHS participants who HIV seroconverted during the follow-up period were excluded from the analysis (figure 1). All participants provided informed consent, and the study was approved by each participating institution’s Institutional Review Board.

Data collection

CIMT and focal carotid plaques were measured by high-resolution B-mode ultrasonography according to previously published procedures [21] at a baseline substudy visit between 2004 and 2006, and at a final substudy visit between 2010 and 2013. All sites used a standardized protocol, and outcome measures were obtained at a centralized reading center (University of Southern California) [20, 22]. The coefficient of variation for repeated measures of CIMT in the WIHS cohort has been published previously [20]. Citrate plasma hsCRP was obtained at the baseline substudy visit on fasting samples obtained in duplicate and measured by a nephelometric immunoassay (Dade-Behring BN II) [23]. Demographic, clinical, and laboratory data were collected by standardized protocols at the WIHS core visit closest to the baseline substudy visit.

Outcome measures

Primary outcomes measures were baseline CIMT, presence of any baseline focal plaques, change in CIMT, and focal plaque progression. CIMT was measured at a 1-cm segment of the right common carotid artery far wall just distal to the carotid bifurcation. Focal plaque was defined as an area of focal IMT > 1.5 mm in any of the 6 imaged segments: near and far walls of the common carotid artery, the carotid bifurcation, and the internal carotid artery [22]. Change in CIMT was defined as the difference between the final and baseline CIMT measurements. Focal plaque progression was defined as the number of new plaques formed in each participant between the baseline and final visits.

AIDS. Author manuscript; available in PMC 2019 May 15.
Measurement of covariates

HIV infection was determined by serologic testing using ELISA and confirmed with Western blot assays. Plasma HIV RNA levels (viral load) were quantified using nucleic-acid-sequence-based amplification assays with a lower limit of quantification of 80 copies/ml (bioMérieux, Boxtel, NC), total peripheral CD4 T cell counts were measured with standard flow cytometric methods. CD4 T cell nadir was defined as the lowest CD4 T cell count prior to ART initiation. ART use was defined as the use of three or more antiretroviral medications. History of clinical CVD was defined as a history of MI, angina, revascularization, transient ischemic attack or stroke. Diabetes was defined as fasting glucose ≥126 mg/dl, glycated hemoglobin (HbA1c) ≥6.5% or self-reported anti-diabetic medication use. Chronic hepatitis C virus (HCV) infection was defined as a positive enzyme immunoanalysis (EIA) and detectable HCV RNA. Lipid levels were obtained following an 8-hour fast. Estimated glomerular filtration rate (eGFR) was determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Age, race/ethnicity, crack/cocaine use, current smoking status, and antihypertensive and lipid-lowering medication use were self-reported.

Statistical analysis

Baseline characteristics of HIV-infected and HIV-uninfected participants were compared by chi-square for categorical variables, and Student’s t-tests or Wilcoxon rank-sum tests for continuous variables, as appropriate. For each outcome, hsCRP was analyzed as a categorical variable with a cutpoint of ≥3 mg/l, and as a continuous (natural log-transformed) variable. Because chronic HCV is associated with lower hsCRP levels, we also assessed the difference in hsCRP by HIV serostatus after excluding all participants with chronic HCV.

Multivariable linear and logistic regression models were used to assess the association of baseline hsCRP with baseline CIMT, and with the presence of baseline focal plaques, respectively. Multivariable linear regression and Poisson regression models were used to assess the association of baseline hsCRP with change in CIMT, and with focal plaque progression, respectively. After checking for collinearity, models were adjusted for age, race/ethnicity, systolic blood pressure, antihypertensive and lipid-lowering medication use, low-density lipoprotein (LDL) cholesterol, diabetes, history of CVD, eGFR, current smoking status, crack/cocaine use, and HCV. For each model, we assessed the interaction between dichotomized hsCRP (above or below 3 mg/l) and HIV status; non-significant interaction terms were removed from the model. Separate analyses by HIV status were conducted, and models for HIV-infected individuals were also adjusted for CD4 count, CD4 nadir, HIV viral load, and ART use. Finally, we examined the association of baseline hsCRP with subclinical CVD progression outcomes among HIV-infected women with persistent virologic suppression defined as an HIV viral load <80 copies/ml at all substudy visits while on continuous ART. Consistent with prior studies, we allowed for one virologic “blip” if the viral load remained <500 copies/ml. We also performed the same analyses among HIV-infected women who did not have persistent virologic suppression.
Analyses were conducted using SAS v9.4 (SAS Institute, Cary, NC). Statistical significance was determined using a p-value of <0.05.

Results

Baseline characteristics

1,870 WIHS participants participated in the carotid ultrasound study. Of these, 788 had more than one carotid ultrasound and baseline hsCRP. Five women were excluded for HIV seroconversion, so 783 (572 HIV-infected and 211 HIV-uninfected) women were included in this analysis (figure 1). The median [interquartile range (IQR)] time between baseline and final carotid artery ultrasound was 6.6 (6.4-7.0) years. Baseline characteristics stratified by HIV status are shown in Table 1. The median age at the first substudy visit was 41 years. 62% of the women were black and 29% were Hispanic. HIV-infected women had lower baseline body mass index (BMI), systolic blood pressure, high-density lipoprotein (HDL) cholesterol, and prevalence of diabetes, higher HCV prevalence, and similar LDL levels as HIV-uninfected women. Three percent of women in each group had a history of clinical CVD, and the average 10-year Framingham CVD risk [27] in both groups was 1%. More HIV-uninfected than HIV-infected women were current smokers and used crack/cocaine. Among HIV-infected participants, the median CD4 count was 452 cells/mm$^3$; 46% had HIV viral load <80 copies/ml, and 62% were on ART. Median (IQR) baseline hsCRP was higher among HIV-uninfected women than HIV-infected women [3.2(0.9-7.7) vs. 2.2(0.8-5.3) mg/l, p=0.005], but baseline focal plaques and median CIMT were not different between groups. In women without chronic HCV, there was a trend toward higher median baseline hsCRP among HIV-uninfected women compared with HIV-infected women that was not statistically significant [3.4(1.0-7.9) vs. 2.6(1.2-5.6) mg/l, p=0.08].

Association of hsCRP with baseline subclinical CVD

The interaction between HIV status and dichotomized hsCRP was not statistically significantly associated with either baseline CIMT or baseline focal plaques (p=0.20 and 0.72, respectively). After multivariable adjustment, there was no association between dichotomized hsCRP and baseline CIMT among all women [estimated mean difference high vs. low hsCRP -3.5 μm (95% confidence interval [CI]: -19.0-12.1)] (figure 2a). High baseline hsCRP was positively associated with focal plaque prevalence among all women [adjusted odds ratio (aOR) 1.31 (95%CI:0.67-2.67)], but the association was not statistically significant (figure 2b). Similar associations were observed when hsCRP was analyzed as a continuous variable (data not shown).

Association of hsCRP with progression of subclinical CVD

There was no statistically significant association of an interaction of HIV status and dichotomized hsCRP with CIMT progression (p=0.67). After multivariable adjustment, dichotomized hsCRP was positively associated with CIMT progression among all women (estimated mean difference high vs. low hsCRP 11.4 μm (95%CI: -2.3-25.1), although this association was not statistically significant (figure 2c). However, high baseline hsCRP was positively associated with focal plaque progression among HIV-uninfected women [adjusted rate ratio (aRR) 5.97 (95%CI: 1.46-24.43)], but not among HIV-infected women [aRR
0.81 (95% CI: 0.47-1.42), p=0.042 for interaction (figure 2d). Among 143 persistently virologically suppressed women, there was no statistically significant association between high baseline hsCRP and carotid plaque progression [aRR 0.55 (95% CI: 0.14-2.20)], or CIMT change [adjusted mean difference 4.5 μm (95% CI: -16.1-25.2)]. Similar associations were observed when hsCRP was analyzed as a continuous variable (data not shown). Finally, among the 379 women without persistent virologic suppression, there was no statistically significant association between high baseline CRP and carotid plaque progression [aRR 0.92 (95% CI: 0.51-1.65)], or CIMT change [adjusted mean difference 9.4 μm (95% CI: -4.9-23.7)]. Similar associations were observed when hsCRP was analyzed as a continuous variable (data not shown).

Discussion

In a well-characterized cohort of HIV-infected and at-risk HIV-uninfected women with similar 10-year Framingham risk scores, we report that baseline plasma hsCRP levels ≥3 mg/l are positively associated with progression of focal carotid plaques among HIV-uninfected, but not HIV-infected, women. We did not find any statistically significant association between hsCRP levels and baseline prevalence of subclinical CVD, nor did we find any statistically significant association between baseline hsCRP and CIMT progression, although there was a trend towards greater CIMT progression with high baseline hsCRP in both groups. Both groups had low Framingham CVD risk and similar subclinical CVD outcomes at baseline. Although HIV infected participants had lower systolic blood pressure, BMI, and prevalence of diabetes, and higher HDL cholesterol than HIV-uninfected participants, these differences were small and unlikely to be clinically significant. Rates of smoking in both groups was higher than the national average [28], and were even higher among HIV-uninfected participants. Similarly, crack and/or cocaine use was higher among HIV-uninfected participants, although current crack/cocaine use was low overall.

We also report higher baseline hsCRP levels in the HIV-uninfected group. This finding was somewhat unexpected because HIV infection has been shown to be positively associated with hsCRP elevation [29]. However, this association seems to be stronger in men than women [30, 31], which may account for differences between our study and others that have included men. Furthermore, hsCRP levels increase with ART administration in men and women [23]. In our analysis, only 62% of HIV-infected women were on ART, which may contribute to the lower hsCRP in that group. This discrepancy may be due in part to the higher rate of chronic HCV in the HIV-infected group. CRP is synthesized by hepatocytes, and prior data have shown that HCV infection is associated with lower plasma hsCRP [26, 32]. Indeed, when all HCV-infected participants were excluded from the analysis, the difference in hsCRP was no longer statistically significant. However, since HCV status was included in the multivariable models, this difference should not affect our overall conclusions. It is also possible that other causes of inflammation, including smoking status and crack/cocaine use, which were higher in the HIV-uninfected group, contributed to the higher baseline hsCRP in this population. Finally, HIV-infected participants had a higher rate of lipid-lowering medication use, although the overall use was low (6% vs. 3%). It is possible that more statin use among HIV-infected women contributed to the lower hsCRP in
this group, but it is unlikely to be a major factor since the overall prevalence of statin use in both groups was very low.

This study adds to a growing body of literature concerning CVD biomarkers in the HIV population. HsCRP is positively associated with CVD events in HIV-infected persons in most observational studies [16, 33, 34]. Its association with subclinical CVD measures in this population is more variable [15], possibly due to different mechanisms of atherogenesis, including the greater role of innate and adaptive immune activation in the setting of HIV infection [30, 35]. In our study, the lack of association between baseline hsCRP and subclinical CVD progression outcomes among HIV-infected women both with and without persistent virologic suppression, unlike in HIV-uninfected women, suggests there are factors beyond HIV viremia that contribute to subclinical CVD progression in HIV-infected women. Therefore, it is possible that hsCRP, which is positively associated with atherosclerosis and MI in the general population, may not be associated as strongly with these outcomes in persons living with HIV.

Our study has limitations. Its retrospective design limits our ability to control for all potential confounders. We used subclinical rather than clinical endpoints. Although carotid artery plaques and CIMT are correlated with CVD events in the general population [36], their association with CVD in the HIV-infected population is unknown. Also, we examined only two measures of atherosclerosis at the carotid artery. Examination of other vessels and other measures of atherosclerosis, such as echogenicity and arterial stiffness, may yield different results. In addition, our cohort was composed of relatively young women with few CVD risk factors and limited clinical CVD. It is possible that the association of hsCRP with subclinical CVD progression would have become apparent with longer follow-up. In addition, as with any multivariable modeling, we were limited in the number of predictors that we could use without over-fitting our models, and were unable to account for all possible covariates that might contribute to CVD risk including duration of HIV infection, duration of protease inhibitor therapy, and abacavir use [37]. Finally, our findings may not be generalizable to men. However, an important scientific strength of this study is the inclusion of women, especially those from racial and ethnic minorities, who have been historically underrepresented in both HIV and CVD clinical trials [38, 39].

In conclusion, we report that hsCRP predicts focal carotid artery plaque progression in HIV-uninfected, but not HIV-infected, women. These findings suggest that hsCRP is not a reliable biomarker for CVD in women in the setting of HIV infection, which could be because the pathogenesis of subclinical CVD may be different in HIV-infected women. Further investigation of alternative CVD biomarkers and the pathogenesis of CVD in the setting of HIV infection is warranted.

**Acknowledgments**

Data in this manuscript were collected by the Women’s Interagency HIV Study (WIHS). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH). WIHS (Principal Investigators): Atlanta WIHS (Ighovwerha Ofotokun and Gina Wingood), U01-AI-103408, Bronx WIHS (Kathryn Anastos), U01-AI-035004; Brooklyn WIHS (Howard Minkoff and Deborah Gustafson), U01-AI-031834; Chicago WIHS (Mardge Cohen and Audrey French), U01-AI-034993; Metropolitan Washington WIHS (Seble Kassaye), U01-AI-034994; Connie Wofsy Women’s HIV Study, Northern
California (Ruth Greenblatt, Bradley Aouizerat, and Phyllis Tien), U01-AI-034989; WIHS Data Management and Analysis Center (Stephen Gange and Elizabeth Golub), U01-AI-042590; Southern California WIHS (Joel Milan), U01-HD-032632 (WIHS I – WIHS IV). The WIHS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), and the National Institute on Mental Health (NIMH). Targeted supplemental funding for specific projects is also provided by the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Deafness and other Communication Disorders (NIDCD), and the NIH Office of Research on Women’s Health. WIHS data collection is also supported by UL1-TR000004 (UCSF CTSA), and UL1-TR000454 (Atlanta CTSA). Other funding sources include R01HL126543 to R. C. K., R01HL132794 to R. C. K., R01HL083760 to R. C. K., R01HL095140 to R. C. K., K01-HL-137557 to D. B. H. and 1K23AI114407 to A. N. S. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

13. Mincu RI, Janosi RA, Vinereanu D, Rassaf T, Totzeck M. Preprocedural C-Reactive Protein Predicts Outcomes after Primary Percutaneous Coronary Intervention in Patients with ST-elevation

AIDS. Author manuscript; available in PMC 2019 May 15.


Figure 1.
Flow diagram for eligibility for study analysis.
Figure 2.
Association of high (≥3 mg/l) vs. low (<3 mg/l) baseline hsCRP with (a) baseline focal plaques, (b) baseline CIMT, (c) focal plaque progression, and (d) CIMT change. Models are adjusted for age, race/ethnicity, systolic blood pressure, antihypertensive and lipid-lowering medication use, low-density lipoprotein (LDL) cholesterol, diabetes, history of CVD, eGFR, current smoking status, crack/cocaine use, and HCV. Models for HIV-infected also adjusted for CD4 count, CD4 nadir, HIV viral load, and ART use.
Abbreviations: hsCRP, high-sensitivity C-reactive protein; MD, mean difference; OR, odds ratio; LCL, lower confidence limit; UCL, upper confidence limit; CIMT, carotid intima-media thickness; RR, rate ratio.
Table 1
Baseline demographic and clinical data for all women and by HIV serostatus

<table>
<thead>
<tr>
<th>Characteristic, median (IQR) or n (%)</th>
<th>Entire cohort (n=783)</th>
<th>HIV-positive (n=572)</th>
<th>HIV-negative (n=211)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>40.6 (35.2-46.7)</td>
<td>40.8 (35.3-46.8)</td>
<td>40.6 (34.3-46.5)</td>
<td>0.51</td>
</tr>
<tr>
<td>Follow-up time (years)</td>
<td>6.6 (6.4-7.0)</td>
<td>6.6 (6.4-7.0)</td>
<td>6.6 (6.4-7.0)</td>
<td>0.39</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td>0.36</td>
</tr>
<tr>
<td>White, non-Hispanic</td>
<td>57 (7)</td>
<td>45 (8)</td>
<td>12 (6)</td>
<td></td>
</tr>
<tr>
<td>Black, non-Hispanic</td>
<td>484 (62)</td>
<td>344 (60)</td>
<td>140 (66)</td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>225 (29)</td>
<td>169 (30)</td>
<td>56 (27)</td>
<td></td>
</tr>
<tr>
<td>Other, non-Hispanic</td>
<td>17 (2)</td>
<td>14 (2)</td>
<td>3 (1)</td>
<td></td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>117 (109-127)</td>
<td>116 (108-127)</td>
<td>120 (111-132)</td>
<td>0.007</td>
</tr>
<tr>
<td>Diastolic blood pressure, mm Hg</td>
<td>71 (64-79)</td>
<td>71 (64-78)</td>
<td>71 (65-80)</td>
<td>0.55</td>
</tr>
<tr>
<td>Antihypertensive medication use</td>
<td>142 (18)</td>
<td>109 (19)</td>
<td>33 (16)</td>
<td>0.27</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>175 (150-201)</td>
<td>174 (149-201)</td>
<td>177 (154-204)</td>
<td>0.26</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dl</td>
<td>47 (39-58)</td>
<td>46 (37-56)</td>
<td>52 (43-63)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dl</td>
<td>102 (79-124)</td>
<td>102 (78-123)</td>
<td>103 (79-125)</td>
<td>0.40</td>
</tr>
<tr>
<td>Triglycerides, mg/dl</td>
<td>104 (73-152)</td>
<td>112 (77-158)</td>
<td>90 (66-127)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Lipid-lowering medication use</td>
<td>42 (5)</td>
<td>36 (6)</td>
<td>6 (3)</td>
<td>0.06</td>
</tr>
<tr>
<td>Diabetes</td>
<td>106 (14)</td>
<td>69 (12)</td>
<td>37 (18)</td>
<td>0.047</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>28.3 (24.3-33.5)</td>
<td>27.6 (24.1-32.1)</td>
<td>30.3 (25.3-37.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>eGFR, ml/min/1.73 m² (CKD-epi)</td>
<td>100.9 (87.2-114.2)</td>
<td>101.5 (86.1-115.0)</td>
<td>99.8 (87.7-111.3)</td>
<td>0.81</td>
</tr>
<tr>
<td>History of clinical CVD*</td>
<td>25 (3)</td>
<td>18 (3)</td>
<td>7 (3)</td>
<td>0.90</td>
</tr>
<tr>
<td>Framingham risk score</td>
<td>8 (3-12)</td>
<td>8 (3-12)</td>
<td>9 (3-13)</td>
<td>0.43</td>
</tr>
<tr>
<td>10-year CVD risk by FRS</td>
<td>1% (1%-1%)</td>
<td>1% (1%-1%)</td>
<td>1% (1%-2%)</td>
<td>0.13</td>
</tr>
<tr>
<td>Current smoker</td>
<td>374 (48)</td>
<td>257 (45)</td>
<td>117 (55)</td>
<td>0.011</td>
</tr>
<tr>
<td>Crack/cocaine use</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>456 (58)</td>
<td>355 (62)</td>
<td>101 (48)</td>
<td></td>
</tr>
<tr>
<td>Former</td>
<td>259 (33)</td>
<td>180 (32)</td>
<td>79 (37)</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>65 (8)</td>
<td>34 (6)</td>
<td>31 (15)</td>
<td></td>
</tr>
<tr>
<td>Current alcohol use</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>399 (51)</td>
<td>314 (55)</td>
<td>85 (40)</td>
<td></td>
</tr>
<tr>
<td>1-7 drinks/week</td>
<td>311 (40)</td>
<td>214 (38)</td>
<td>97 (46)</td>
<td></td>
</tr>
<tr>
<td>&gt;7 drinks/week</td>
<td>70 (9)</td>
<td>41 (7)</td>
<td>29 (14)</td>
<td></td>
</tr>
<tr>
<td>Chronic HCV</td>
<td>154 (20)</td>
<td>122 (21)</td>
<td>32 (15)</td>
<td>0.054</td>
</tr>
</tbody>
</table>

HIV-associated characteristics

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4 count, cells/mm³</td>
<td>--</td>
<td>452 (288-658)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>CD4 nadir, cells/mm³</td>
<td>--</td>
<td>281 (161-409)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>HIV viral load, cop/ml</td>
<td>--</td>
<td>180 (80-6900)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Undetectable (&lt;80 cop/ml)</td>
<td>--</td>
<td>260 (46)</td>
<td>--</td>
<td></td>
</tr>
</tbody>
</table>

* AIDS. Author manuscript; available in PMC 2019 May 15.
<table>
<thead>
<tr>
<th>Characteristic, median (IQR) or n (%)</th>
<th>Entire cohort (n=783)</th>
<th>HIV-positive (n=572)</th>
<th>HIV-negative (n=211)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 1000 cop/ml</td>
<td>--</td>
<td>84 (15)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>≥ 1000 cop/ml</td>
<td>--</td>
<td>227 (40)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>History of clinical AIDS</td>
<td>--</td>
<td>270 (47)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>ART use</td>
<td>--</td>
<td>356 (62)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>NRTI use</td>
<td>--</td>
<td>355 (62)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>NNRTI use</td>
<td>--</td>
<td>136 (24)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>PI use</td>
<td>--</td>
<td>209 (37)</td>
<td>--</td>
<td></td>
</tr>
</tbody>
</table>

Outcome variables

<table>
<thead>
<tr>
<th></th>
<th>Entire cohort (n=783)</th>
<th>HIV-positive (n=572)</th>
<th>HIV-negative (n=211)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsCRP</td>
<td>2.4 (0.9-5.7)</td>
<td>2.2 (0.8-5.3)</td>
<td>3.2 (0.9-7.7)</td>
<td>0.005</td>
</tr>
<tr>
<td>hsCRP ≥ 3.0 mg/l</td>
<td>344 (46)</td>
<td>234 (43)</td>
<td>110 (53)</td>
<td>0.019</td>
</tr>
<tr>
<td>Baseline carotid plaques</td>
<td>54 (7)</td>
<td>39 (7)</td>
<td>15 (8)</td>
<td>0.78</td>
</tr>
<tr>
<td>Focal plaque progression **</td>
<td>80 (11)</td>
<td>65 (12)</td>
<td>15 (8)</td>
<td>0.11</td>
</tr>
<tr>
<td>Baseline CIMT, μm</td>
<td>709 (652-779)</td>
<td>707 (649-776)</td>
<td>714 (657-794)</td>
<td>0.20</td>
</tr>
<tr>
<td>Final CIMT, μm</td>
<td>727 (674-804)</td>
<td>724 (670-803)</td>
<td>740 (684-814)</td>
<td>0.25</td>
</tr>
<tr>
<td>CIMT change **, μm</td>
<td>25.4 (-1.0-49.0)</td>
<td>19 (-2.0-49.0)</td>
<td>23.0 (1.0-48.0)</td>
<td>0.83</td>
</tr>
</tbody>
</table>

Abbreviations: HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease; FRS, Framingham risk score; HCV, hepatitis C virus; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; hsCRP, high-sensitivity C-reactive protein; CIMT, carotid artery intima-media thickness

* Clinical CVD defined as a history of MI, stroke/TIA, angina, peripheral arterial disease, or revascularization procedure

** Plaque progression defined as increase in number of total plaques from baseline visit to final visit

*** CIMT change defined as difference in CIMT from baseline visit to final visit